Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2023-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for DongKoo Bio & Pharma. It details the meeting date, location, agenda items (such as financial statement approval, director appointments, and dividend proposals), and voting procedures. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their votes, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2023-03-13 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a formal notice regarding the closure of the shareholder register to determine eligibility for the upcoming Annual General Meeting (AGM). It specifies the record date, the period for suspension of name changes, and the purpose (holding the 40th Annual General Meeting). Since this is a regulatory announcement regarding meeting logistics and shareholder rights rather than the meeting presentation itself or a proxy statement, it falls under the general regulatory filing category.
2022-12-15 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement regarding the setting of a record date for shareholder registry closure to determine eligibility for future dividends. It explicitly states that it is not the dividend declaration itself, but the procedural step to establish the record date for the 40th fiscal year-end dividend. Since it pertains to dividend-related shareholder rights and record dates, it falls under the category of dividend-related announcements.
2022-12-15 Korean
수시공시의무관련사항(공정공시)
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Dongkoo Bio & Pharma regarding their planned cash dividend for the 2022 fiscal year. It specifies the dividend amount per share, the record date, and the total estimated payout. Since the document is an official announcement of a dividend amount rather than a full financial report or a proxy statement, it falls under the 'Notice of Dividend Amount' category.
2022-12-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). This document details changes in share ownership by major shareholders and special related parties, specifically noting changes due to collateral loan repayments. In the context of global financial reporting, this falls under the category of 'Major Shareholding Notification' (MRQ).
2022-11-23 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Dongkoo Bio&Pharma, covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.